Home Cart Sign in  
Chemical Structure| 516480-79-8 Chemical Structure| 516480-79-8

Structure of BML-277
CAS No.: 516480-79-8

Chemical Structure| 516480-79-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

BML-277 is a selective Chk2 (checkpoint kinase 2) inhibitor with IC50 of 15 nM.

Synonyms: Chk2 Inhibitor II; C 3742; Checkpoint Kinase 2 Inhibitor II

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of BML-277

CAS No. :516480-79-8
Formula : C20H14ClN3O2
M.W : 363.80
SMILES Code : O=C(C1=CC=C2C(NC(C3=CC=C(OC4=CC=C(Cl)C=C4)C=C3)=N2)=C1)N
Synonyms :
Chk2 Inhibitor II; C 3742; Checkpoint Kinase 2 Inhibitor II
MDL No. :MFCD08276917
InChI Key :UXGJAOIJSROTTN-UHFFFAOYSA-N
Pubchem ID :9969021

Safety of BML-277

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • Chk2

    Chk2, IC50:15 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
Human peripheral blood mononuclear cells 2.5 µM 24 hours To evaluate the radioprotective effects of BML-277 on radiation-induced apoptosis, results showed that BML-277 significantly reduced the number of radiation-induced apoptotic cells. PMC11093554
HuT 78 cells 13.40 µM 24 hours To evaluate the radioprotective effects of BML-277 on radiation-induced apoptosis, results showed that BML-277 did not exhibit significant protective effects in HuT 78 cells. PMC11093554
IM-9 cells 13.45 µM 24 hours To evaluate the radioprotective effects of BML-277 on radiation-induced apoptosis, results showed that BML-277 significantly reduced the number of radiation-induced apoptotic cells. PMC11093554
Tu212 cells 0.01, 0.1, 0.25, 0.5, 1, 2.5, 5, 10 μM 24 hours To evaluate the effect of BML-277 on Tu212 cell growth, results showed BML-277 inhibited cell proliferation in a dose-dependent manner PMC7351626
HEP-2 cells 5 μM 24, 48 hours To evaluate the effect of BML-277 on HEP-2 cell growth, results showed BML-277 inhibited cell proliferation in a time-dependent manner PMC7351626
LoVo-OR cells 10 μM 72 hours To evaluate the effect of BML-277 on HR efficiency, results showed that BML-277 significantly reduced HR efficiency. PMC9596403

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NOD/SCID mice Colo205-OR xenograft tumour model Intraperitoneal injection 1 mg/kg and 3 mg/kg Thrice per week for 2 weeks To evaluate the inhibitory effect of BML-277 on OR CRC tumour growth, results showed that BML-277 significantly suppressed the Colo205-OR tumour growth. PMC9596403

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.75mL

0.55mL

0.27mL

13.74mL

2.75mL

1.37mL

27.49mL

5.50mL

2.75mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories